Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Capital Expenditures (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Capital Expenditures for 7 consecutive years, with $50000.0 as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Capital Expenditures fell 51.92% year-over-year to $50000.0, compared with a TTM value of $83000.0 through Dec 2019, down 23.15%, and an annual FY2024 reading of $515000.0, up 214.02% over the prior year.
  • Capital Expenditures was $50000.0 for Q4 2019 at Larimar Therapeutics, up from $31000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $456000.0 in Q3 2016 and bottomed at -$196000.0 in Q2 2016.
  • Average Capital Expenditures over 5 years is $83388.9, with a median of $27000.0 recorded in 2015.
  • The sharpest move saw Capital Expenditures skyrocketed 2218.75% in 2015, then plummeted 259.35% in 2016.
  • Year by year, Capital Expenditures stood at $371000.0 in 2015, then grew by 22.91% to $456000.0 in 2016, then plummeted by 94.08% to $27000.0 in 2017, then soared by 285.19% to $104000.0 in 2018, then crashed by 51.92% to $50000.0 in 2019.
  • Business Quant data shows Capital Expenditures for LRMR at $50000.0 in Q4 2019, $31000.0 in Q2 2019, and $2000.0 in Q1 2019.